NCT02735252 is a NA clinical trial of Systemic therapy in Prostate Cancer, sponsored by University of California, San Francisco.

Who is sponsoring NCT02735252?

NCT02735252 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT02735252?

Interventions in NCT02735252: Systemic therapy, StrataNGS.

What condition does NCT02735252 study?

NCT02735252 studies Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer.

Is NCT02735252 still recruiting?

NCT02735252 is currently active, enrolled. Last updated 12 November 2025.

Last reviewed 2025-11-12 · How we verify

NCT02735252

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Active, enrolled NA Last updated 12 November 2025

What this trial tests

NA trial testing Systemic therapy in Prostate Cancer in 156 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

25 May 2016

Primary endpoint
31 March 2027

31 March 2027

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	156
Start date	25 May 2016
Primary completion	31 March 2027
Estimated completion	31 March 2027
Sites	1 location across United States

Drugs / interventions tested

Systemic therapy — full drug profile →
StrataNGS

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Advanced Renal Cell Carcinoma — all drugs for Advanced Renal Cell Carcinoma →
Advanced Urothelial Carcinoma — all drugs for Advanced Urothelial Carcinoma →
Genitourinary Cancer — all drugs for Genitourinary Cancer →

Sponsor

University of California, San Francisco

Who can join

18 and older, male only, with Prostate Cancer or Advanced Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will be enrolled in into one of several parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted Therapy/Investigational therapeutic, (E) DNA damage response pathway, (F) Aggressive variant disease, (G1) Castration-sensitive ADT naïve and ADT \< 3 months), or (G2) Castration-sensitive pre-treated with sub-optimal PSA nadir \>0.2 ng/ml, (R) metastatic renal cell carcinoma and metastatic and (U) urothelial carcinoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Chou J, Egusa EA, Wang S, Badura ML, et al · · 2023 · cited 51× · PMID 36351060 · DOI 10.1158/0008-5472.can-22-1433
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.
Di Nunno V, Gatto L, Santoni M, Cimadamore A, et al · · 2018 · cited 15× · PMID 30319966 · DOI 10.3389/fonc.2018.00397
Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
Chen E, Cario CL, Leong L, Lopez K, et al · · 2021 · cited 10× · PMID 34250416 · DOI 10.1200/po.20.00428

Verify or expand the search:

Other trials of Systemic therapy

Trials testing the same drug.

NCT06254248 — Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07274774 — SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07156617 — A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based · not yet recruiting
NCT06427252 — The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC W · Phase 2 · active not recruiting
NCT06422247 — Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy · completed

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02735252 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 12 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02735252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing